The Food and Drug Administration has placed two Astrazeneca drugs under observation, after two studies have linked the administration of these drugs with some cases of death. However, the FDA has invited patients to continue using the drugs in question, arguing that there do not appear to be any higher risks associated with their use than those already established. Despite this reassurance, Astrazeneca shares lost 3.5% to 2430 pernce. From Finance and Markets of 08-10-07
